Navigation Links
FDA approves additional dosage strengths of Vyvanse
Date:1/3/2008

PHILADELPHIA January 3, 2008 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for three additional dosage strengths for the attention deficit hyperactivity disorder (ADHD) treatment, VYVANSE™ (lisdexamfetamine dimesylate). Shire expects the three additional dosage strengths of 20 mg, 40 mg and 60 mg will be available in retail pharmacies in the second quarter of 2008 to supplement the existing 30 mg, 50 mg and 70 mg dosage strengths currently available in pharmacies throughout the country.

Shire is pleased that physicians will soon have the benefit of a wider range of VYVANSE dosage strengths which they can prescribe to help manage the ADHD symptoms of their patients, said Matt Emmens, Chief Executive Officer of Shire Pharmaceuticals. In its first six months of availability, more than 500,000 VYVANSE prescriptions have been dispensed, indicating that physicians see VYVANSE as an effective treatment option for their patients.

Dose titration, the process of incrementally increasing or decreasing the dose of a medication, is a widely used method in clinical practice to help achieve optimal efficacy and tolerability for each patient. The option of having dosage strengths with smaller increments allows for a more gradual titration of medication and may help the physician tailor the treatment for each individual patient.

Shire has also experienced early success with managed care coverage for VYVANSE, which is now preferred on three of the five largest national plans. According to available national data, more than 85 percent of lives in the United States are covered for VYVANSE in Tier 3 or better, added Emmens. We are optimistic that the formulary coverage for VYVANSE will continue to improve as we move into 2008.

VYVANSE is currently approved in the United States for the treatment
'/>"/>

Contact: Jacelyn Seng
jacelyn.seng@porternovelli.com
212-601-8385
Porter Novelli
Source:Eurekalert

Page: 1 2

Related medicine news :

1. FDA approves Bystolic, a novel beta blocker
2. AASM approves home sleep testing to detect sleep apnea
3. HHS Approves Medicaid Waiver to Create New Indiana Health Plan for Uninsured Hoosiers
4. FDA approves ABILIFY(R) (aripiprazole) as the first medication for add-on treatment of MDD
5. ClearWay Minnesota(SM) Board Approves $2.8 Million for Research Grants
6. FDA Approves the Allergy Treatment Zyrtec(R) for Use Without a Prescription
7. FDA Approves MIRCERA(R): First Renal Anemia Treatment with Monthly Maintenance Dosing
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia
9. US FDA approves ABILIFY for adolescent patients with schizophrenia
10. FDA Approves the Opening of a Phase II Registration Protocol Using REXIN-G(R) for Osteosarcoma in California U.S.A.
11. Illinois Planning Board Approves Central DuPage Hospital Bed Pavilion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... ward off depression among retirees, particularly among those who ... The Journals of Gerontology, Series B: Psychological Sciences ... Internet Use and Depression Among Retired Older Adults in ... report that Internet use reduced the probability of a ... , Late-life depression affects between 5 and 10 ...
(Date:4/17/2014)... Council scientists and their partners have found that their ... the transmission of multiple sexually transmitted infections (STIs) in ... simplex virus 2 (HSV-2), and human papillomavirus (HPV). The ... gel is effective against multiple strains of HIV, and ... all three viruses of at least eight hours prior ...
(Date:4/17/2014)... WINSTON-SALEM, N.C. April 17, 2014 Meaningful ... from advanced cancer of the abdomen when treated ... HIPEC, according to a first-of-its-size analysis by physicians ... Forest Baptist has the largest reported, single-center experience ... Edward A. Levine, M.D., and analysis of 20 ...
(Date:4/17/2014)... world is less than 40 years away from a ... and governments, according to a top scientist at the ... in human history, food production will be limited on ... and energy," said Dr. Fred Davies, senior science advisor ... could become as politically destabilizing by 2050 as energy ...
(Date:4/17/2014)... 17, 2014While 94 per cent of Canadians surveyed said ... newborns for a specific number of genetic conditions, only ... participate in screening that would sequence their newborns, genomes.,Most ... in their first day or two of life in ... their heels and tested for about five to 54 ...
Breaking Medicine News(10 mins):Health News:Internet use may cut retirees' depression 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3
... Revenues increase 166% versus Q1 2007 ... Six new Centers opened to date in 2008, VANCOUVER, May ... revenues of $1.35 million for,the three months ended March 31, 2008 ... an increase of 166%. The Company,s net,loss decreased to $0.96 million ...
... Israel, May 29 Elbit Imaging Ltd.,(Nasdaq: EMITF ... for the,first quarter of 2008., Loss for the ... US$ 1.0 million) of which loss of NIS 27.3 ... holders of,the Company, while profit of NIS 23.8 million ...
... from the Oregon Health & Science University Cancer Institute ... hope to many patients. , Researchers have discovered that ... can occur in a gene called the KIT gene. ... and mucosal melanomas, which are less common, but highly ...
... bacteria break their metabolic processes into chunks. That may ... have now figured out the factors that tend to ... Santa Fe Institute and Stanford University, together with Anat ... University, constructed the metabolic networks of many species of ...
... Society for Therapeutic Radiology has selected the recipients of ... bestows. Christopher Rose, M.D., FASTRO, and Joel Tepper, M.D., ... 50th Annual Meeting in Boston during the Gold Medal ... "It seems particularly fitting that we recognize these two ...
... risk of dying within month, study finds , , THURSDAY, May ... more likely to die within 30 days than stroke patients ... Seizures may be a sign of significant brain injury and ... This study found that the overall incidence of seizures within ...
Cached Medicine News:Health News:CRH Medical reports Q1 2008 results 2Health News:CRH Medical reports Q1 2008 results 3Health News:CRH Medical reports Q1 2008 results 4Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 2Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 3Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 4Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 5Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 6Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 7Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 8Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 9Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 10Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 11Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 12Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 13Health News:OHSU Cancer Instutute researchers find abnormalities in gene for melanoma 2Health News:ASTRO announces 2008 gold medalists 2
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. ... a U.S. provisional patent application concerning composition of matter, ... achieve targeted tumor cell death.  This ... noncoding double stranded RNA molecules (VSRNAs) which interfere with ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... Forecast – Worldwide Analysis ... Market Analysis Insulin ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... 2010 Reportlinker.com announces that a new market research ... Global Pulse Oximeters Industry ... the worldwide markets for Pulse Oximeters in Thousands of ... and covers non-invasive pulse oximeters only: Product Types – ...
... Nov. 17, 2010 Cyberonics, Inc. (Nasdaq: CYBX ... Officer, and Greg Browne, Chief Financial Officer, will present at ... York on Tuesday, November 30, 2010 at 1:30 PM ET. ... no formal slides will be presented.  Piper Jaffray will host ...
Cached Medicine Technology:Reportlinker Adds Global Pulse Oximeters Industry 2Reportlinker Adds Global Pulse Oximeters Industry 3Reportlinker Adds Global Pulse Oximeters Industry 4Reportlinker Adds Global Pulse Oximeters Industry 5Reportlinker Adds Global Pulse Oximeters Industry 6Reportlinker Adds Global Pulse Oximeters Industry 7Reportlinker Adds Global Pulse Oximeters Industry 8Reportlinker Adds Global Pulse Oximeters Industry 9Reportlinker Adds Global Pulse Oximeters Industry 10Reportlinker Adds Global Pulse Oximeters Industry 11Reportlinker Adds Global Pulse Oximeters Industry 12Reportlinker Adds Global Pulse Oximeters Industry 13Reportlinker Adds Global Pulse Oximeters Industry 14Reportlinker Adds Global Pulse Oximeters Industry 15Reportlinker Adds Global Pulse Oximeters Industry 16Reportlinker Adds Global Pulse Oximeters Industry 17Reportlinker Adds Global Pulse Oximeters Industry 18Reportlinker Adds Global Pulse Oximeters Industry 19Reportlinker Adds Global Pulse Oximeters Industry 20Reportlinker Adds Global Pulse Oximeters Industry 21Reportlinker Adds Global Pulse Oximeters Industry 22Reportlinker Adds Global Pulse Oximeters Industry 23Reportlinker Adds Global Pulse Oximeters Industry 24Reportlinker Adds Global Pulse Oximeters Industry 25Reportlinker Adds Global Pulse Oximeters Industry 26Reportlinker Adds Global Pulse Oximeters Industry 27Cyberonics to Present at 22nd Annual Piper Jaffray Health Care Conference 2
The Shandon Manual Staining Station is ideal for special processes, frozen sections, special stains and low volume procedures....
The Shandon Finesse 315 low-cost precision microtome is ergonomically designed to consistently produce high quality routine paraffin sections without user strain or fatigue....
The new Shandon HistocentreTM 3 is an integral part of the workflow in Histology laboratories, representing a workstation that complements any automatic tissue processor....
Shandon HistoWave is the answer to rapid tissue processing. It reduces time for fixation, tissue processing, decalification, immunochemistry and special stains....
Medicine Products: